Neoleukin NL-201 MoA animation. De novo protein development platform

MoA explainer animation for Neoleukin Therapeutics' lead program, NL-201 for IR and communication. https://lnkd.in/gEYngaBf — see full case study.

An example of the combination of two types of animation — simplified 3D and scientifically-accurate 3D molecular visualizations. A scientifically rigorous, eye-catching, and cost-effective option that works well in a variety of use cases.

We are grateful to Jonathan Drachman, Robert Ho, Daniel-Adriano Silva, and Julie Rathbun for working with us and for their kind feedback.
"Visual Science created a vibrant animation that will help us in our investor relations and communications efforts, illustrating our de novo protein design approach to developing novel therapies for patients." – Robert Ho (ex CFO, Neoleukin Therapeutics).

Neoleukin Therapeutics (NASDAQ: NLTX )
is a pioneer in de novo protein development, leveraging computational methods to create new therapies.

The Neuleukin Therapeutics team has developed an approach to creating new - de novo - proteins that overcome the limitations of naturally-occurring proteins, with potential for use in precise, targeted treatments. The NT approach enables synthesis of de novo therapeutic proteins with advantages such as improved efficacy, lower toxicity, increased stability, improved pharmacokinetic properties, or alternate routes of administration.

Видео Neoleukin NL-201 MoA animation. De novo protein development platform канала Visual Science